my fiancé
cutting-edge research across her interests, late 2025 → 2026
The space matured fast in 2025. The independently meaningful work is the 2025 PMC paper validating at-home urinary hormone measurements specifically in postpartum and perimenopause transitions — exactly the populations these devices are now marketed to but were never originally validated for. Inito has two peer-reviewed validation studies; Oova still has zero published. Mira's 2025 internal lab study claims 7× accuracy advantages but it's company-run.
Until 2025, all device validation was in healthy cycling women under 35. Perimenopause-specific accuracy data is brand new and changes who should trust which device.
PMC12040536 — postpartum/perimenopause validation
The newest finding: a 2025 pharmacovigilance comparison of tirzepatide vs. semaglutide shows the theoretical "estrogen dump" from rapid lipolysis does not appear as disproportionate adverse-event signal — but menstrual irregularities, oral contraceptive failure, and rebound dysmenorrhea are real signals. A separate 2025 case report shows refractory dysmenorrhea responding to a GLP-1 — opening a small but novel research lane.
The field shifted from "do they affect cycles?" to "can they treat gynecologic conditions directly?"
PMC12908611 — tirzepatide vs semaglutide · PMC11821293 — GLP-1 for dysmenorrhea
The CDC and mainstream genetics groups are pushing back on the "avoid folic acid" narrative. People with MTHFR variants metabolize folic acid adequately at 400 mcg. The nuance retained: monitor homocysteine, MMA, and SAMe:SAH ratios rather than treating genotype alone. Jeffrey Bland's PLMI published 2025 work integrating COMT + FUT2 + MTHFR for perimenopause — the trio matters more than MTHFR alone (COMT governs estrogen clearance, FUT2 governs B12 uptake).
Functional medicine converging on tested biomarkers; conventional medicine accepting personalization.
CDC MTHFR statement · PLMI perimenopause genetics
DUTCH has crossed into mainstream-adjacent acceptance for estrogen metabolite ratios (2-OH:16-OH, 4-OH methylation) — those have actual mechanistic literature. The HPA-axis claims remain weakly supported. Use it for estrogen metabolism, not for cortisol storytelling.
Choline 930 mg/day — the Cornell trial's 14-year cognitive follow-up is being submitted fall 2025 (first long-arc human RCT data). Most prenatals still ship 0–200 mg. FullWell, Needed, and Ritual Essential Prenatal come closest to the 930 mg target with food.
Omega-3 — a Frontiers in Nutrition 2025 paper found omega-3 added to prenatals reduced preterm and SGA rates (outcome data, not surrogate). ACOG's 2024–2025 guidance now accepts ≥250 mg DHA daily. DHA:EPA ratios shifting toward 5:1 DHA-dominant.
Lily Nichols + Lisa Hendrickson-Jack — Real Food for Fertility (late 2024) is now the dominant preconception text.
Field moving from "deficiency avoidance" to "performance-targeted dosing."
Cornell choline 14-yr follow-up · Frontiers omega-3/preterm
The 2025 AJOG meta-analysis: CGM reduces HbA1c and likely LGA across all diabetes-in-pregnancy categories. The DiGest trial (Diabetes Care 2025) defined actionable GDM targets: mean glucose <110 mg/dL, ≥90% TIR (63–140), <10% TAR at 29 weeks. Dexcom released 2025 Clinical Pearls for pregnancy. Off-label use in non-diabetic pregnancies is growing in concierge MFM.
The year CGM in pregnancy stopped being fringe — targets are now numerical, not vibes-based.
AJOG 2025 meta-analysis · Dexcom 2025 pregnancy pearls
The 2025 systematic review (Hourigan et al., AJOG): modest, real microbiome modulation; no serious adverse events across 512 infants; insufficient evidence for routine use outside trials. The ACTIVATE trial is the one to watch — randomized, focused on allergy outcomes in C-section infants. The 2024 Song et al. RCT showed higher Ages-and-Stages neurodev scores at 6 months — first neurodev signal.
2025 systematic review · ACTIVATE trial
Elizabeth Larkam & Madeline Black — Pilates Applications for Health Conditions (two-volume, 2025) is the new clinical reference, organized by multi-system and locomotor conditions, integrating biotensegrity and Anatomy Trains. Larkam's March 2025 Polestar workshop on Applied Biotensegrity is the cleanest CE entry point.
Tom Myers / Anatomy Trains in Motion (Karin Gurtner's adaptation) — the cert pilates teachers take when they want serious fascia training.
Moving Fascia® (Ana Barretxeguren) — Oct 2025 cohort, blends fascia + nervous-system regulation.
First clinical reference text aimed at Pilates teachers working alongside PTs with specific conditions — fills a gap that previously forced teachers to over-medicalize or oversimplify.
Pilates Applications for Health Conditions (2025)
No major curriculum overhaul in 2025, but Polestar's Pilates Hour webinar program and Balanced Body's MOTR + bridge programs are the active CE channels. Soteria Pilates teacher training is the rising contemporary cert blending classical + biomechanics + fascia. Erika Bloom's 2025/2026 certification ($8K early-bird) is the high-end NYC private-clientele track.
2025 RCT (PMC12150949) — 8 weeks of Pilates significantly improved menopausal symptoms and sexual function vs. control. Small (n=30) but the first RCT specifically targeting menopause-symptom modulation via Pilates. The 2024 Pilates-vs-PFMT RCT for postmenopausal urinary incontinence: comparable outcomes — meaningful because PFMT was previously the only "evidence-based" option.
The 2025 inflection: studios mixing classical + Lagree + jumpboard cardio in single classes rather than picking a lane. Sculptformer and Xformer enable this hardware-wise. Jumpboard plyometric programming is being formalized — Speir Pilates' Cardio Sculpt on-demand is the most rigorous online curriculum. Contrology revival — small but real countermovement back to Joseph Pilates' original 34 mat exercises and original-spring tensions (Power Pilates NYC, The Pilates Standard).